Specimen Collection for Translational Studies in Hidradenitis Suppurativa
- PMID: 31434914
- PMCID: PMC6704132
- DOI: 10.1038/s41598-019-48226-w
Specimen Collection for Translational Studies in Hidradenitis Suppurativa
Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory disorder characterized by painful nodules, sinus tracts, and scars occurring predominantly in intertriginous regions. The prevalence of HS is currently 0.053-4%, with a predominance in African-American women and has been linked to low socioeconomic status. The majority of the reported literature is retrospective, population based, epidemiologic studies. In this regard, there is a need to establish a repository of biospecimens, which represent appropriate gender and racial demographics amongst HS patients. These efforts will diminish knowledge gaps in understanding the disease pathophysiology. Hence, we sought to outline a step-by-step protocol detailing how we established our HS biobank to facilitate the formation of other HS tissue banks. Equipping researchers with carefully detailed processes for collection of HS specimens would accelerate the accumulation of well-organized human biological material. Over time, the scientific community will have access to a broad range of HS tissue biospecimens, ultimately leading to more rigorous basic and translational research. Moreover, an improved understanding of the pathophysiology is necessary for the discovery of novel therapies for this debilitating disease. We aim to provide high impact translational research methodology for cutaneous biology research and foster multidisciplinary collaboration and advancement of our understanding of cutaneous diseases.
Conflict of interest statement
A.S.B. and G.A.O. are investigators for Eli Lilly. A.S.B. recieved honorarium for speaking at the 77th Annual Society for Investigative Dermatology meeting - AbbVie Sponsored Symposium. J.M.S. is a consultant for Allergen and Co-Founder of LifeSprout, which had no impact or conflicts related to this manuscript. L.S.M. has received grant support from AstraZeneca, MedImmune, Pfizer, Regeneron Pharmaceuticals, Moderna Therapeutics, and Boehringer Ingelheim, and is on the scientific advisory board for Integrated Biotherapeutics, and is a shareholder of Noveome Biotherapeutics, which are all unrelated to the work reported in this manuscript. A.A. received grant funding or honorarium from AbbVie, Galderma, LEO Pharma, Novartis, Sanofi, and Valeant, and hese relationships or funds had no impact or conflicts related to this manuscript. M.A.L. has received consulting honorarium from Abbvie, Incyte, and Xbiotech, but these relationships had no impact on this manuscript. G.A.O. received honorarium from AbbVie for participation on their Hidradenitis Suppurativa Advisory Board. Y.D., U.J.O., Q.Q.Q., C.C.-R., D.W.W., M.L.K., R.J.M., L.P., H.B.N., L.A.B., W.D.S., J.A.C., S.M.M., O.A., K.P.B., D.K., H.L., C.A.D., R.A., J.W.F., M.J.K., S.K., and L.A.G. declare no potential conflicts of interest.
Figures
References
-
- Vaidya T, Vangipuram R, Alikhan A. Examining the race-specific prevalence of hidradenitis suppurativa at a large academic center; results from a retrospective chart review. Dermatol. Online J. 2017;23:12. - PubMed
